Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Community-based Screening and Treatment for Malaria in Western Kenya
NCT02987270Phase 3Completed
- Start
- Apr 2013
- Primary completion
- Aug 2015
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of dihydroartemisinin + piperaquine in Falciparum malaria (PF) (2 arms). Primary endpoint: Incidence of malaria infection at 2 years. Started Apr 2013; status: completed.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on NCT02987270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987270.